Not enough patients saw at least a 20% improvement in their arthritis, as measured by criteria set by the American College of Rheumatology, after 12 weeks of taking the drug, the company said. The randomized, double-blind trial evaluated 322 adults with moderate-to-severe rheumatoid arthritis. Some adults took various dosages of duvelisib, while others took a placebo.

Infinity will continue to focus on using duvelisib for the treatment of blood cancers such as lymphoma and leukemia. In September,
AbbVie Inc.
ABBV -1.59%
and Infinity unveiled a collaboration to develop and commercialize duvelisib for this purpose.

Under the agreement, Infinity will receive an up-front payment of $275 million and is eligible to receive up to $530 million in additional milestone payments, the companies said.

Meanwhile, GW Pharmaceuticals Thursday also reported that its investigational product Sativex, for the treatment of pain in patients with advanced cancer, also didn't meet its goals in a clinical trial.

Shares of Infinity are up about 30% in the past 12 months through Wednesday’s close.